Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Study to Evaluate the Efficacy and Safety of Activated T Lymphocytes (ATL) in Hepatocellular Carcinoma (HCC) Patients After Curative Treatment

NCT05304481 is registered in ClinicalTrials.gov with Lukas Biomedical Inc. as lead sponsor.

NCT NCT05304481
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05304481 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Study to Evaluate the Efficacy and Safety of Activated T Lymphocytes (ATL) in Hepatocellular Carcinoma (HCC) Patients After Curative Treatment
Lead sponsor
Lukas Biomedical Inc.
Phase
Phase 2
Overall status
Recruiting
Start date
May 14, 2022
Completion date
October 30, 2028
Enrollment
95 (estimated)
Sites
14

Conditions

As the registry lists them; a condition with its own page is linked.

hepatocellular carcinoma